- Table of Contents
We validate the specificity of these antibodies to MASP2 by testing them on tissues known to express MASP2 positively and negatively. Browse below to find the MASP2 antibody that suites your experiment. We have 4 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Mannan-binding lectin serine protease 2.
|peptidase S1 family|
EC 3.4.21; EC 220.127.116.11; mannan-binding lectin serine peptidase 1 pseudogene 1; mannan-binding lectin serine peptidase 2; mannan-binding lectin serine protease 1 pseudogene 1; mannan-binding lectin serine protease 2; Mannose-binding protein-associated serine protease 2; MAP19; MASP1P1; MASP-2; MBL-associated plasma protein of 19 kD; MBL-associated serine protease 2; small MBL-associated protein; sMAP
|Sequence:||1; NC_000001.11 (11026523..11047239, complement)|
If you are looking for a reliable MASP2 mAb, you should read this article. In this article, you will find details on MASP-2 Antibody, its Clinical applications, and Epitopes. The information provided here will help you in choosing the right MASP2 mAb for your specific research. Besides, you will find some useful information on the MASP2 Marker.
Omeros' anti-MASP-2 program is focused on the development of antibodies that inhibit MASP-2. MASP-2 is unique among other lectins, and its inhibition may help to treat and prevent hemolytic uremic syndrome, atypical hemolytic uremia, transplant-related complications, and immune-related disorders. Antibodies that inhibit MASP-2 are being tested for their efficacy in clinical trials.
After identifying the gene for this specific anti-MASP-2 antibody, the Bio-Rad team developed a phage display-based screening methodology to identify antibodies to MASP-2 in rat plasma. Phage display blocking isolates phages containing the gene for the antibody. The phages were then washed extensively, and only those that bound to the antibody sequence were eluted for further panning under the same blocking conditions. This method ensured that antibodies would be isolated from the phages.
The company has developed over 12,000 antibodies in various fields, including cancer, developmental biology, neurosciences, and inflammation. All Boster products have undergone validation on known positive and negative samples. For the highest affinity and specificity, Boster offers ELISA kits and other immunological reagents that can be used in multiple research methods. And Boster provides technical support to its customers. And the company is committed to bringing science to the public.
In a recent study, a collaborator of Omeros, Professor Schwaeble, identified proteins that drive the activation of the alternative pathway. His discovery will advance Omeros' MASP-2 program and lead to new therapeutics that target this pathway. The company has also filed a series of patent applications that claim a broad intellectual property position related to the alternative pathway. The company also plans to continue the research with the antibody and is seeking partners for its drug development.
The Anti-MASP-2 antibody from Boster bio is a highly effective, proven solution for anti-MASP-2 research. It was shown to have efficacy in pneumococcal killing in a PVC assay, and a human immunoglobulin inactivation test. Interestingly, the antibody also had a positive effect on bacterial growth. It also demonstrated anti-MASP-G, a type of granulocytokeratin that is essential for the growth of some pathogens.
The MASP2 marker targets the complement serine protease in cells. Its polymorphisms are associated with susceptibility or protection from infectious diseases. In this study, researchers identified polymorphisms in MASP2.
This MASP2 antibody is a highly specific marker for the SARS virus. It is highly effective in the identification of the viral agent in patients. This antibody has several uses, and the use of this specific antigen in a variety of clinical applications is a great example. Using it to identify SARS-CoV-2 antibody responses will allow physicians to diagnose the disease earlier. It is also useful in identifying rare diseases, including encephalitis, hepatitis C, and HIV.
In a previous study, researchers found that MASP2 polymorphisms were associated with various milk production traits, including CH50, 305-day milk yield, and protein percentage. Cows with homozygous genotype CC had higher CH50 and protein percentage than their counterparts in genotype AA and ACT. In addition, cows with genotype AC were more resistant to mastitis, indicating that milk produced by these animals may be improved.
Omeros Corporation believes that it has discovered a protein that activates the alternative pathway of the complement system. The complement system is an important part of the immune system and plays a central role in the inflammatory response. Tissue damage and microbial infection activate the complement system. The MASP2 protein is known to be required for the proper functioning of the lectin pathway. Inhibition of this protein does not interfere with the classical complement activation pathway. Moreover, studies have shown that MASP2 polymorphisms are associated with colorectal cancer, liver cancer, and rheumatoid arthritis, and it is linked to tuberculosis susceptibility.
Molecular targeting of the MASP2 marker has shown promising results in limiting neurological deficits after ischemic stroke in a mouse model. Moreover, it has been demonstrated that this enzyme is involved in the activation of microglia, which causes the formation of pro-inflammatory amoebae. As such, MASP-2 inhibition can help limit the post-stroke neurological deficits and improve the associated ischemic lesion size.
Omeros' MASP-2 program has focused on the development of antibodies that inhibit MASP-2, which plays a crucial role in activating the lectin pathway. It has also conducted several in vivo studies evaluating the potential of MASP-2 inhibitors as a preventative and therapeutic therapy for a variety of immune-related disorders, including atypical hemolytic uremic syndrome. In addition to this, Omeros has filed multiple patent applications claiming broad intellectual property positions on this protein.
While MASP2 plasma levels have a dual effect in HIV infection, there are some indications that the MASP2 marker is an acute-phase protein. Its plasma levels may serve as a new reference for the diagnosis of upper respiratory tract infection in children. Further, MASP2 plasma levels have been associated with the risk of ischemic stroke and the MASP2 rs147270785*A allele is a protective factor.
The MASP2 protein contains two distinct epitopes. Each of these epitopes is located on the first and second b strands. The first epitope spans the region 45-59 and the second region 63-77. These two regions are marked by cyan ribbons, which are indicated in Table 2.
MASP2 is a part of the lectin pathway of complement activation. The human coronaviruses activate the MASP-2 protein, causing aberrant complement activation in patients. Among the potential consequences of this aberrant complement activation is aggravated lung injury. This condition can be fatal. As such, the MASP2 marker provides a means to identify the protein responsible for this condition.
In addition to targeting the MASP2 protein, a MASP-2 inhibitory agent is available for use during a variety of conditions. It can be administered before or after exposure to radiation, and in some cases can reduce the symptoms of acute radiation syndrome. The MASP-2 inhibitory agent is also useful in treating patients with reduced complement factors. It can also be used as a first line therapy for patients who cannot undergo plasmapheresis.
As a result of the MASP-2 dependent activation of the complement system, a MASP-2 inhibitor will inhibit intravascular hemolysis. This inhibition is expected to provide a significant treatment benefit to patients with PNH. The inhibitors inhibit both opsonization and intravascular hemolysis. The use of MASP-2 inhibitors is expected to have a beneficial impact in the treatment of all PNH patients.
Several studies have shown that the MASP-2 marker is highly targeted. When a functional monoclonal antibody targeting MASP-2 inhibits the complement-dependent complement activation system, it enhances the killing response. Inhibition of MASP-2 is a valuable therapeutic option. However, in order to use this inhibitor, a human MASP-2 inhibitor must inhibit all five lectins.
Although the MASP2 protein is highly conserved, its antigenic region is still poorly understood. However, a MASP inhibitory agent can be administered before, during, or after a trigger event. These trigger events include drug exposure, infection, organ transplant, and pregnancy. However, this approach is not a cure for aHUS. It is, however, one of the most effective treatment options available for this disease.